Results 51 to 60 of about 3,904 (178)

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials [PDF]

IMPORTANCE The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown.
Parkes, Gareth, Sanchez Gonzalez, Yuri, Boland, Brigid S, Panaccione, Remo, Bossuyt, Peter, Kalabic, Jasmina, Ferrante, Marc, D'Haens, Geert, Cheng, Ling, Levine, Phillip, Atreya, Raja, Schreiber, Stefan, Chen, Su, Armuzzi, Alessandro, Duan, W Rachel, Neimark, Ezequiel, Wu, Kaichun, Biedermann, Luc, Loftus, Edward V Jr, Pivorunas, Valerie, Biedermann, Luc; https://orcid.org/, Wallace, Kori, Melmed, Gil Y, Rahier, Jean-François, Louis, Edouard, Shu, Lei, Loftus, Edward V, Hisamatsu, Tadakazu, Siegmund, Britta, Dewit, Olivier, D'Cunha, Ronilda, Colombel, Jean-Frederic, INSPIRE and COMMAND Study Group, INSPIRE and COMMAND Study, Peyrin-Biroulet, Laurent   +34 more
core   +1 more source

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors

European Medical Journal Dermatology, 2020
With the recent advancements of biologic therapies that block IL-23, there is increasing need for analysis of which biologics are most efficacious in treatment of plaque psoriasis.
Nicole L. Bolick, Rima I. Ghamrawi, Steven R. Feldman   +2 more
doaj  

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Efficacy and safety of risankizumab for active psoriatic arthritis : 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial [PDF]

, 2022
Objectives Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA ...
Papp, Kim, Wang, Zailong, Ostor, Andrew, Alperovich, Gabriela, Soliman, Ahmed M., Blanco, Ricardo, Asnal, Cecilia, Van den Bosch, Filip, Lu, Wenjing, Eldred, Ann, Barcomb, Lisa, Aelion, Jacob, Kivitz, Alan   +12 more
core   +1 more source

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study [PDF]

, 2022
Background: Recent knowledge on the key role of interleukin (IL)23/17 axis in psoriasis pathogenesis, led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody specifically targeting IL23.
Camela, Elisa, Potestio, Luca, Megna, Matteo, Fabbrocini, Gabriella, Ruggiero, Angelo   +4 more
core   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

Rheumatology and Therapy
Introduction Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety.
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M. Soliman, Michael Chen, Byron Padilla, Frank Behrens   +12 more
doaj   +1 more source